Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for LLY
+0.53 (0.83%)
After Hours: 64.25 0.00 (0.00%)
Jul 23, 6:20PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 63.80 - 64.44
52 week 47.53 - 64.44
Open 63.93
Vol / Avg. 5.56M/3.77M
Mkt cap 71.92B
P/E 17.96
Div/yield 0.49/3.05
EPS 3.58
Shares 1.12B
Beta 0.38
Inst. own 76%
Jul 24, 2014
Q2 2014 Eli Lilly Earnings Release - 9:30AM EDT - Add to calendar
Jul 24, 2014
Q2 2014 Eli Lilly Earnings Conference Call - 9:00AM EDT - Add to calendar
Jun 16, 2014
Eli Lilly Plans To Share Phase III Dulaglutide Data
Jun 11, 2014
Eli Lilly at Goldman Sachs Healthcare Conference
Jun 3, 2014
Eli Lilly Analyst Meeting to Review the Data Presented at ASCO 2014
May 28, 2014
Eli Lilly at Sanford C Bernstein Strategic Decisions Conference
May 7, 2014
Eli Lilly at EBD Group ChinaBio Partnering Forum
May 5, 2014
Eli Lilly Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 15.54% 20.27%
Operating margin 17.83% 23.24%
EBITD margin - 29.76%
Return on average assets 8.34% 13.45%
Return on average equity 16.23% 28.92%
Employees 37,925 -
CDP Score - 86 B


Lilly Corporate Center
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company�s products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company�s new molecular entities (NMEs) are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Empagliflozin-BI10773, Enzastaurin, Ixekizumab, Necitumumab,, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In July 2014, Anthera Pharmaceuticals Inc acquired Sollpura (liprotamase), a investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 49
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 54
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 60
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 45
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 51
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 48
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 47
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 49
Bio & Compensation  - Reuters
Barton R. Peterson Senior Vice President - Corporate Affairs and Communications
Age: 55
Bio & Compensation  - Reuters